Jump to the top of the page

Showing 940 – 950 of 1159 results

  • Anaplan Inc Initiation

    William Blair & Company initiated research coverage of Anaplan, Inc. (PLAN $71.20), a cloud-based provider of connected planning software.

  • LifeStance Health Group, Inc. Initiation

    William Blair initiated research coverage of LifeStance Health Group, Inc. (LFST $27.63), the largest provider of outpatient mental health services in the United States.

  • BTRS Holdings Inc Initiation

    William Blair & Company initiated research coverage of BTRS Holdings, Inc. (BTRS $17.00). BTRS Holdings (Billtrust) is a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce.

  • Lonza Group AG Initiation

    William Blair & Company initiated research coverage of Lonza Group AG (LONN-SWX CHF 587.80). Lonza is the largest global contract development and manufacturing organization (CDMO), with particularly strong market share positions in biologics drug substance, small molecule high potency active pharmaceutical ingredients, antibody drug conjugates, and cell therapy.

  • Sprinklr, Inc Initiation

    William Blair initiated research coverage of Sprinklr, Inc. (CXM $19.51). Sprinklr is a leading unified customer experience management (CXM) platform that enables large enterprises to engage with customers on modern channels like social media, messaging, live chat, and text, operating across more than 30 such channels.

  • Sovos Brands Inc Initiation

    William Blair initiated research coverage of Sovos Brands, Inc. (SOVO $14.18). Sovos is a growing food company that innovates and markets disruptive and differentiated brands, including Rao’s, Noosa, Birch Benders, and Michael Angelo’s. It products are premium and convenient and sold in all major classes of retail trade.

  • Larimar Therapeutics Inc Initiation

    William Blair & Company initiated research coverage of Larimar Therapeutics, Inc. (LRMR $15.44), a clinical-stage company developing proprietary intracellular-targeted therapeutics for orphan diseases, with an initial focus on Friedreich’s ataxia (FA), for which there are no FDA-approved therapies.

  • Allbirds Inc Initiation

    William Blair initiated research coverage of Allbirds, Inc. (BIRD $20.29), a fast-growing footwear and apparel lifestyle brand featuring products made from naturally derived materials.

  • Tempest Therapeutics Inc Initiation

    William Blair initiated research coverage of Tempest Therapeutics, Inc. (TPST $13.96), which is developing a pipeline of small-molecule therapies for novel disease targets, including TPST-1495, a dual EP2/EP4 antagonist, to treat prostaglandin-driven cancers.

  • Augmedix Inc Initiation

    William Blair initiated research coverage of Augmedix, Inc. (AUGX $3.63), a leading provider of technology-enabled medical documentation and clinical support services.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures